Gilead fails to overturn $752m BMS patent verdict
02-04-2020
Kite teams up with Sangamo to treat cancer
26-02-2018
Life sciences companies face off over ‘Juno’ trademark
26-07-2017
Novartis pays Juno $12m in cancer patent licensing deal
07-04-2015
wildpixel / iStockphoto.com
Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kite, Sloan Kettering Institute, Juno, cancer immunotherapy, US Patent and Trade Office, Patent Trial and Appeal Board, Food and Drug Administration, paten
